View Financial HealthCitius Pharmaceuticals 配当と自社株買い配当金 基準チェック /06Citius Pharmaceuticals配当金を支払った記録がありません。主要情報n/a配当利回り-380.0%バイバック利回り総株主利回り-380.0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesCitius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.999966 million.Apr 25New major risk - Share price stability Apr 24Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.000001 million.Apr 24Insufficient new directors Mar 01Citius Pharmaceuticals, Inc., Annual General Meeting, Apr 06, 2026Feb 25New major risk - Financial position Feb 16Citius Pharmaceuticals, Inc. Provides Nasdaq Listing Compliance UpdateFeb 14Forecast breakeven date pushed back to 2027 Dec 26New major risk - Share price stability Dec 24Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.999749 million.Oct 22Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.999749 million.Oct 21New major risk - Financial position Aug 14Forecast breakeven date pushed back to 2026 Aug 13Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.001962 million.Jun 13Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $6.001962 million.Jun 10New major risk - Share price stability Jun 09Citius Pharmaceuticals, Inc. announced that it has received $1 million in fundingJun 04Forecast breakeven date moved forward to 2025 May 18New major risk - Shareholder dilution May 01Citius Pharmaceuticals, Inc. announced a financing transactionApr 19Consensus EPS estimates fall from profit to US$1.79 loss Apr 13Price target decreased by 85% to US$5.67 Apr 11Consensus EPS estimates fall from profit to US$0.67 loss, revenue upgraded Apr 06Forecast breakeven date pushed back to 2026 Apr 04Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.999873 million.Apr 03Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.Apr 01Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare & Medicaid ServicesFeb 08New major risk - Shareholder dilution Jan 21Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 10, 2025Jan 17Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $3.000006 million.Jan 09Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.Jan 08+ 1 more updateForecast breakeven date moved forward to 2025 Dec 30Price target decreased by 44% to US$54.00 Nov 26Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to ApprovalNov 26Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.Nov 19Forecast breakeven date pushed back to 2026 Nov 18New major risk - Share price stability Nov 16Nasdaq Hearings Panel Grants Citius Pharmaceuticals' Request to Continue its Listing on The Nasdaq Capital Market to Regain Compliance with the Bid Price Rule on or before December 3, 2024Nov 14Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (Keytruda®) and Lymphir™ in Cancer Patients with Recurrent Solid TumorsNov 12Citius Pharmaceuticals, Inc. Provides Non-Compliance UpdateSep 12New minor risk - Market cap size Sep 04Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.Aug 13Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaAug 08Price target increased by 22% to US$4.67 Jul 16Forecast breakeven date pushed back to 2026 Jun 03Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionMay 22Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.May 01Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell LymphomaApr 11We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth CarefullyApr 06New minor risk - Share price stability Apr 01The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)Mar 14Forecast breakeven date pushed back to 2026 Feb 23Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for LymphirFeb 14New minor risk - Market cap size Feb 01Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024Jan 24Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage CathetersJan 02New major risk - Financial position Dec 31New minor risk - Profitability Dec 29We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn RateDec 08Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint InhibitorNov 01New minor risk - Share price stability Oct 25Citius Pharmaceuticals, Inc. Announces Changes to its Audit CommitteeSep 26Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock MarketSep 16Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIRSep 09Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 TrialAug 11Price target decreased by 21% to US$3.17 Aug 01Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?Aug 01Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell LymphomaJul 30Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of HemorrhoidsJun 21Consensus EPS estimates fall by 24% May 21We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business GrowthApr 12Forecast breakeven date pushed back to 2025 Apr 11Price target increased by 25% to US$5.00 Mar 29Forecast breakeven date pushed back to 2025 Feb 16Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of DirectorsFeb 08Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn SituationDec 25Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023Dec 23Price target decreased to US$3.60 Nov 16Insufficient new directors Nov 16Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK Sep 28Citius Pharmaceuticals GAAP EPS of -$0.06 Aug 11Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash WiselyAug 05Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK Jul 12Citius Pharmaceuticals: Hoping For A Turnaround Strategy Jul 05Price target increased to US$4.00 Apr 27Insufficient new directors Apr 27Critical Care Biopharma - Citius Pharmaceuticals Apr 13Forecast breakeven date pushed back to 2024 Apr 08Citius: 2022 Is A Year Of Catalysts Mar 28Forecast breakeven date moved forward to 2023 Jan 21We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business GrowthDec 04Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization Sep 26Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In GrowthAug 28決済の安定と成長配当データの取得安定した配当: CTXRの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: CTXRの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Citius Pharmaceuticals 配当利回り対市場CTXR 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (CTXR)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.2%アナリスト予想 (CTXR) (最長3年)n/a注目すべき配当: CTXRは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: CTXRは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: CTXRの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: CTXRが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/30 15:13終値2026/04/30 00:00収益2025/12/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Citius Pharmaceuticals, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Jason KolbertD. Boral Capital LLC.Jason McCarthyMaxim GroupMichael OkunewitchMaxim Group
Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.999966 million.Apr 25
Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.000001 million.Apr 24
Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.999749 million.Oct 22
Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.999749 million.Oct 21
Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.001962 million.Jun 13
Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $6.001962 million.Jun 10
Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.999873 million.Apr 03
Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.Apr 01
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare & Medicaid ServicesFeb 08
Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $3.000006 million.Jan 09
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to ApprovalNov 26
Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.Nov 19
Nasdaq Hearings Panel Grants Citius Pharmaceuticals' Request to Continue its Listing on The Nasdaq Capital Market to Regain Compliance with the Bid Price Rule on or before December 3, 2024Nov 14
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (Keytruda®) and Lymphir™ in Cancer Patients with Recurrent Solid TumorsNov 12
Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.Aug 13
Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaAug 08
Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionMay 22
Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.May 01
Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell LymphomaApr 11
The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)Mar 14
Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for LymphirFeb 14
Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage CathetersJan 02
Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint InhibitorNov 01
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIRSep 09
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell LymphomaJul 30
Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of HemorrhoidsJun 21
